UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
April 14, 2008
ALPHARMA INC.
|
Delaware (State or Other Jurisdiction of Incorporation) |
1-8593 (Commission File Number) |
22-2095212 (IRS Employer Identification No.) |
|
|
440 Route 22, Bridgewater (Address of principal executive offices) |
|
|
|
(866) 322-2525 (Registrant's telephone number, including area code) |
|
|
|
Not Applicable Former name or former address, if changed since last report |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure
Alpharma Inc. (the "Registrant") issued a press release on April 14, 2008. A copy of the Registrant's press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press release issued by Registrant on April 14, 2008. |
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |
|
ALPHARMA INC. (Registrant) By: /s/ Thomas J. Spellman III Thomas J. Spellman III Executive Vice President & Chief Legal Officer & Corporate Secretary |
Date: April 14, 2008